X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Focal Ablation Technique for Intermediate-Risk Prostate Cancer Continues to Show Safety

The NanoTherm therapy system for focal ablation of intermediate-risk prostate cancer continued to show a tolerable safety profile in a recent analysis.

Additional supportive data from stage 2a of a pivotal study of the NanoTherm therapy system for focal ablation of intermediate-risk prostate cancer confirm the initial findings showing that the treatment modality was safe and effective, according to MagForce AG who is responsible for developing the system.1

Results were taken from a 10-patient cohort showing that only minimal treatment-related adverse effects and a tolerable safety profile were reported.

Read the full article here. 

source: Audrey Sternberg - Cancer Network